ArticleIranian journal of medical sciences2025
Associations between Chinese Visceral Adiposity Index and the Risk of Metabolic Dysfunction-associated Steatotic Liver Disease and Liver Fibrosis: A Large Cross-sectional Study.
Article in Iranian journal of medical sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Comparative discriminative ability of CVAI and traditional insulin resistance indices for MAFLD in Chinese adults with type 2 diabetes.Frontiers in endocrinology · 2026Article
- Triglyceride-glucose-waist circumference index: A powerful tool for metabolic dysfunction-associated steatotic liver disease.World journal of hepatology · 2025Review
- Unveiling Liver Disease Risk-The Public Health Implications of Visceral Adiposity Assessment with the Chinese Visceral Adiposity Index: A Letter to the Editor.Iranian journal of medical sciences · 2025Article
- Association between Chinese visceral adiposity index and arterial stiffness among hospital workers in a Chinese tertiary hospital.Diabetology & metabolic syndrome · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The associations between Chinese visceral adiposity index (CVAI) and non-alcoholic fatty liver disease (NAFLD) or hepatic fibrosis in Westerners are not obvious. Furthermore, metabolic dysfunction-associated steatotic liver disease (MASLD) is the new nomenclature of NAFLD, with significantly different diagnostic criteria. The present study aimed to investigate the relationships between CVAI and MASLD or hepatic fibrosis in an American population, as well as to assess the diagnostic value of CVAI for MASLD and fibrosis. Methods: After excluding missing data on calculations of indices, diagnosis of MASLD, and covariates, 3242 participants were selected from the National Health and Nutrition Examination Survey 2017-2020. Multivariate logistic regression analyses and restricted cubic spline (RCS) were used to determine the associations between CVAI and MASLD or fibrosis. The diagnostic capacity was evaluated by the area under the receiver operating characteristic (AUROC) curve. Data were analyzed using R software (version 4.2.2). P<0.05 was considered statistically significant. Results: The risk of MASLD was increased at quartiles 2, 3, and 4 compared with quartile 1 of CVAI (OR [95% CI]=3.66 [2.44-5.63], 7.954 [5.31-12.23], and 14.84 [9.80-23.06], respectively), (P<0.001). The odds ratios (95% CI) of hepatic fibrosis risk were 1.23 [0.67, 2.30], 2.44 [1.39, 4.43], 7.46 [4.36, 13.30] for the quartiles 2, 3, and 4 compared to the lowest quartile (P<0.001). According to RCS, CVAI, MASLD, and fibrosis, all had positive relationships. CVAI had AUROCs of 0.759 and 0.771 for diagnosing MASLD and fibrosis, respectively. Conclusion: The CVAI was positively related to the risk of MASLD or liver fibrosis and could be a novel biomarker for predicting MASLD and fibrosis in the American population.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.